Reviva Pharmaceuticals Holdings, Inc. RVPH 深 沪
交易中 03-27 10:03:37 美东时间
0.7551
-0.029
-3.66%
华盛通- 最 高3.52
- 今 开0.80
- 成交量 2.71万股
- 最 低 0.17
- 昨 收 0.7838
- 总市值 1.14万
- 52周最高 3.52
- 市盈率 静 --
- 换手率 179.35%
- 52周最低 0.17
- 委 比 73.33%
- 总股本 1.51万
- 历史最高 15.10
- 量 比 1.73
- 振 幅 427.40%
- 历史最低 0.17
- 每 手 1
- 风险率
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多What's Behind The Drop In Reviva Pharmaceuticals Stock?
Reviva Pharmaceuticals shares are tumbling Thursday after pricing a $10 million public offering of over 6 million shares at $1.50 per share.
03-20 00:49
Gold Tumbles Over 6%; Accenture Earnings Top Views
U.S. stocks traded lower midway through trading, with the Nasdaq Composite fall...
03-20 00:01
US Stocks Mixed; GDP Growth Tops Expectations
U.S. stocks traded mixed this morning, with the Nasdaq Composite gaining around...
2025-12-23 23:01
Reviva Announces Positive Full Dataset for 1-Year Phase 3 RECOVER Open Label Extension Study Evaluating Brilaroxazine in Schizophrenia
Reviva Pharmaceuticals' Phase 3 RECOVER OLE study of brilaroxazine for schizophrenia demonstrates sustained broad-spectrum efficacy over 1 year, with low adverse events and a 35% discontinuation rate. Positive results across symptom domains, enhanced by improved neuroinflammatory markers, highlight its potential to address unmet needs in schizophrenia treatment.
2025-06-02 11:00
EF Hutton Initiates Coverage On Reviva Pharmaceuticals with Buy Rating, Announces Price Target of $15
EF Hutton analyst Jason Kolbert initiates coverage on Reviva Pharmaceuticals (NASDAQ:RVPH) with a Buy rating and announces Price Target of $15.
2024-09-23 20:36
Reviva To Host Virtual KOL Event To Discuss Vocal Biomarker Data From Phase 3 RECOVER Trial Of Brilaroxazine In Schizophrenia On September 4, 2024
Reviva Pharmaceuticals Holdings, Inc. (NASDAQ:RVPH) ("Reviva" or the "Company"), a late-stage pharmaceutical company developing therapies that seek to address unmet medical needs in the areas of central nervous system (CNS), inflammatory and cardiometabolic diseases, today announced it will host a v...
2024-08-27 20:06
Benchmark Reiterates Speculative Buy on Reviva Pharmaceuticals, Maintains $17 Price Target
Benchmark analyst Bruce Jackson reiterates Reviva Pharmaceuticals (NASDAQ:RVPH) with a Speculative Buy and maintains $17 price target.
2024-08-26 21:55
Reviva Pharmaceuticals Holdings Prices $5 Million Offering
07:05 AM EDT, 08/21/2024 (MT Newswires) -- Reviva Pharmaceuticals (RVPH) said Wednesday it had priced a $5 million offering of 4.8 million shares of common stock and 4.8 million warrants at a combined price of $1.05. The company said the warrants have an exercise price of $0.7964 per share, exercisa...
2024-08-21 19:05
